TRT and testosterone boosters: separating hype from clinical fact

What did @brookerevelsfnp actually say?

The NP's core message is straightforward: men on testosterone replacement therapy need lab monitoring every three months, and testosterone clinics are sometimes dropping the ball. She says patients are arriving with PSA "through the roof," elevated hematocrit putting them at cardiovascular risk, and hormone levels high enough to threaten fertility. Her ask is simple: see a qualified provider and get your labs done.

This is a clinical warning video, not a sales pitch. She's describing a pattern she's seeing in practice, which gives it some credibility. But clinical anecdotes are not data, and a few of her specific claims deserve closer scrutiny before you take them as settled science.

Does the science back this up?

On the broad strokes, yes. The monitoring argument is solid. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend checking hematocrit, PSA, and testosterone levels at three and six months after initiation, then annually. Her "every three months" framing is conservative but defensible, especially in the first year.

The hematocrit concern is well-documented. Testosterone stimulates erythropoiesis, and polycythemia (hematocrit above 54%) is one of the most consistent adverse effects of TRT. A 2017 meta-analysis by Corona et al. in the European Journal of Endocrinology confirmed elevated erythrocytosis risk across testosterone formulations. Elevated hematocrit does increase blood viscosity and thrombotic risk, so the stroke and heart attack warning is not fearmongering.

The PSA-to-prostate-cancer link is where things get murkier, and that deserves its own section.

What did they get wrong (or right)?

The PSA claim is the shakiest part of the video. She says elevated PSA puts men "at risk for prostate cancer," which conflates PSA elevation with cancer causation. PSA is a screening marker, not a diagnosis. TRT can modestly raise PSA in some men, but current evidence does not establish that TRT causes prostate cancer in men with normal prostates. The landmark work by Morgentaler and Traish (2009, European Urology) challenged the long-held belief that testosterone drives prostate cancer progression, and multiple subsequent studies have not found increased incidence in TRT users.

That said, elevated PSA in a TRT patient absolutely warrants urological evaluation. Monitoring is appropriate. The problem is framing PSA elevation as synonymous with cancer risk rather than as a flag requiring follow-up.

The fertility point she makes is accurate. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH, which tanks intratesticular testosterone and sperm production. Wenker et al. (2015, Journal of Urology) showed significant oligospermia or azoospermia in men on TRT. This is real, and it's underreported at many testosterone clinics, especially direct-to-consumer ones.

• Hematocrit monitoring: accurate and evidence-backed
• Fertility suppression risk: accurate and clinically significant
• PSA monitoring: appropriate recommendation, but the cancer framing is oversimplified
• "Every three months" monitoring: conservative but within guideline parameters

What should you actually know?

If you're on TRT, the monitoring she's describing is not optional. It's standard of care. The concern about testosterone clinics skipping labs is legitimate. A 2020 analysis by Malik et al. in Urology found that a meaningful proportion of men prescribed testosterone through online or direct-to-consumer platforms had no documented baseline or follow-up labs. That's a real problem.

Here's what monitoring should actually include: total testosterone, hematocrit, PSA (in men over 40 or with risk factors), and a lipid panel. If you're concerned about fertility, add FSH, LH, and a semen analysis before starting TRT, not after. Once you're on testosterone, recovering spermatogenesis can take six to eighteen months, and in some men it doesn't fully return.

The broader takeaway is that TRT is not a supplement. It's a hormone therapy with real physiological consequences that require clinical oversight. An NP flagging inadequate monitoring is doing the right thing. The mechanism details she leaned on are mostly sound, with the PSA-cancer link being the one place she overstated her case.